Epidemiology & Biostatistics, McGill University, Montreal, Quebec, Canada.
McGill International TB Centre, Montreal, Quebec, Canada.
BMJ Glob Health. 2020 Jan 20;5(1):e002080. doi: 10.1136/bmjgh-2019-002080. eCollection 2020.
The WHO End TB Strategy calls for a global reduction in the case fatality ratio (CFR) below 5%. India accounts for a third of global tuberculosis (TB) deaths. This systematic review estimated CFRs among Indian patients with TB both during and after treatment.
We systematically searched Medline, Embase and Global Health for eligible studies published between 1 January 2006 and 8 January 2019, including both cohort studies and intervention study control arms that followed Indian patients with TB for fatality either during treatment or post-treatment. From relevant studies we extracted CFRs in addition to study demographics. Study quality was assessed using modified Scottish Intercollegiate Guidelines Network cohort criteria. Sufficiently homogenous studies were pooled using a random effect generalised linear mixed model. A meta-regression was performed to associate study characteristics with resulting CFRs.
218 relevant studies were identified, of which 211 provided treatment phase CFRs. Most patients (92.4%) were treated in the public sector. Quality concerns were identified in 74% of papers. We estimated a pooled treatment phase CFR of 5.16% (95% CI 4.20% to 6.34%) which fell to 3.78% (2.77% to 5.16%) when restricted to 52 high-quality studies. Treatment phase CFRs were higher for paediatric (n=27, 6.50% (2.65% to 10.36%)), drug-resistant (n=43, 14.06% (10.15% to 19.49%)) and HIV-infected (n=35, 10.91% (7.68% to 15.50%)) patients. Nineteen post-treatment CFR studies were too heterogeneous to pool except when restricting to three high-quality studies (2.69% (-0.79% to 6.18%)). Poor study quality (OR=2.27 (2.01 to 2.57)) and tertiary centres patients (OR=1.15 (1.03 to 1.28)) were significantly associated with increased treatment phase case fatality.
Case fatality is a critical measure of the quality of TB care. While India's treatment CFRs are in line with WHO targets, several key patient groups remain understudied and most studies suffer from methodological issues. Increased high-quality reporting on patient outcomes will help improve the evidence base on this topic.
世界卫生组织(WHO)的结核病控制策略呼吁将全球结核病病例病死率(CFR)降低到 5%以下。印度占全球结核病(TB)死亡人数的三分之一。本系统评价评估了印度结核病患者在治疗期间和治疗后的病死率。
我们系统地检索了 Medline、Embase 和全球卫生数据库,以纳入 2006 年 1 月 1 日至 2019 年 1 月 8 日期间发表的合格研究,包括队列研究和干预研究对照臂,这些研究均对印度结核病患者的病死率进行了随访,无论是在治疗期间还是治疗后。从相关研究中,我们提取了病死率以及研究人口统计学数据。使用改良的苏格兰校际指南网络队列标准评估研究质量。对足够同质的研究采用随机效应广义线性混合模型进行汇总。进行了荟萃回归分析,以将研究特征与病死率相关联。
确定了 218 项相关研究,其中 211 项提供了治疗阶段病死率。大多数患者(92.4%)在公共部门接受治疗。74%的论文存在质量问题。我们估计,治疗阶段的病死率为 5.16%(95%CI 4.20%至 6.34%),当限制在 52 项高质量研究中时,病死率降至 3.78%(2.77%至 5.16%)。儿科患者(n=27,6.50%(2.65%至 10.36%))、耐药患者(n=43,14.06%(10.15%至 19.49%))和 HIV 感染患者(n=35,10.91%(7.68%至 15.50%))的治疗阶段病死率更高。19 项治疗后病死率研究差异太大,无法汇总,除非限制在 3 项高质量研究中(2.69%(-0.79%至 6.18%))。较差的研究质量(OR=2.27(2.01 至 2.57))和三级中心患者(OR=1.15(1.03 至 1.28))与治疗阶段病死率增加显著相关。
病死率是衡量结核病护理质量的关键指标。尽管印度的治疗 CFR 符合世卫组织的目标,但一些关键患者群体仍未得到充分研究,而且大多数研究都存在方法学问题。增加关于患者结局的高质量报告将有助于改善这一主题的证据基础。